How long do peptides take to work? Timelines by compound

Science 8 min read Reviewed

Realistic timelines for when different peptide classes reach steady state, when subjective effects typically emerge, and why patience is the hardest part of any protocol.

Contents8
  1. 1The two timelines
  2. 2Steady state: the science
  3. 3When results actually appear
  4. 4Why some people feel nothing
  5. 5The tracking advantage
  6. 6Patience vs adjusting
  7. 7Frequently asked questions
  8. 8References

A common question from anyone starting a new compound is some variation of "when will I feel it?" There are two separate timelines in any protocol, the pharmacokinetic one and the biological one, and mixing them up causes much of the early frustration.

This article sets out both timelines for common peptide classes, using labels and published trials where they exist and saying so where they do not.

The two timelines

Every compound has two separate clocks running once dosing begins.

Timeline 1: Pharmacokinetic steady state. This is the point at which the amount entering the body equals the amount being eliminated, giving a stable plateau of circulating levels. It depends on half-life and dosing frequency. Under first-order elimination, half the drug is removed each half-life, so regular dosing gets to about 97% of steady state after 5 half-lives.1 A peptide with a 2-hour half-life is there in about 10 hours; semaglutide, with a half-life of approximately 1 week, reaches steady state after 4 to 5 weeks of weekly doses, by its label.7

Timeline 2: Subjective and biological results. This is when something is noticed: appetite changes, better sleep, less pain, visible body composition changes. It depends on the mechanism, the downstream processes, the person, the dose, and things outside the compound (training, nutrition, sleep). It is usually longer than the time to steady state and varies between people.

Key concept

Reaching steady state does not mean an effect will be felt at that moment. Steady state means levels have stopped climbing. The processes the compound acts on (tissue repair, receptor signalling, metabolic change) run on their own timescales.

Steady state: the science

The 5 half-life figure is arithmetic on first-order elimination, where 50% is removed each half-life.1 After one half-life of consistent dosing, levels are at about 50% of steady state; after two, 75%; three, 87.5%; four, 93.75%; five, 96.875%.

So compounds with short half-lives reach steady state within hours and long half-life compounds take weeks. The half-life sets how quickly levels stabilise and how much they swing between doses. For more, see Understanding Peptide Saturation & Steady State.

Compound Half-life Time to steady state Category
BPC-157 < 30 min (rats, dogs)2 < 2.5 hours Healing
TB-500 No human data3 Not known Healing
GHK-Cu Not found3 Not known Healing / Skin
Ipamorelin ~2 hours (IV, volunteers)4 ~10 hours GH Peptide
CJC-1295 (DAC) 5.8-8.1 days5 ~29-41 days GH Peptide
Testosterone Enanthate Not on label6 By week 6 (weekly, Xyosted) Testosterone
Semaglutide ~1 week7 4-5 weeks GLP-1
Tirzepatide ~5 days8 4 weeks GLP-1 / GIP
MK-677 (Ibutamoren) Not sourced here Not given GH Secretagogue
PT-141 ~2.7 hours9 Used as needed, by label Melanocortin

The range is wide. On its animal half-life, BPC-157 would reach steady state within a few hours, while CJC-1295 with DAC, at 5.8 to 8.1 days, would take over a month. For short half-life compounds, each dose largely stands alone and levels swing between doses; for long half-life compounds, each dose layers on the last. Where the table says not known, no human pharmacokinetic study was found.

When results actually appear

Steady state is arithmetic; results are biology. The timelines below come from labels and published trials where they exist. Where only community reports exist, the section says so and gives no timeline.

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide)

GLP-1 agonists have the most trial data of any class here. The phase 3 obesity trials ran 68 to 72 weeks, with titration built in.1011

  • Early weeks: in STEP 1, nausea and diarrhea were the most common adverse events with semaglutide, typically transient and mild to moderate, subsiding with time.10
  • Dose escalation: Wegovy starts at 0.25 mg weekly for weeks 1 to 4 and steps up every 4 weeks (0.5, 1, 1.7 mg) to the maintenance dose from week 17.12
  • During escalation: in SURMOUNT-1, tirzepatide's gastrointestinal adverse events occurred primarily during the 20-week dose-escalation period.11
  • Endpoint: mean body weight change was -14.9% at week 68 with semaglutide 2.4 mg (placebo -2.4%) in STEP 1, and -15.0% to -20.9% at week 72 with tirzepatide 5 to 15 mg (placebo -3.1%) in SURMOUNT-1.1011

With titration, the maintenance dose of Wegovy is not reached until week 17, so a person is still stepping up the dose while also watching for results.12

Healing peptides (BPC-157, TB-500, GHK-Cu)

For healing peptides, human data is thin. A 2025 systematic review of BPC-157 found 36 studies, 35 preclinical and 1 clinical; in preclinical models, BPC-157 improved outcomes in muscle, tendon, ligament and bone injuries, and no clinical safety data were found.13 The FDA says it has not identified human exposure data for TB-500.3 So there is no published human timeline for these compounds, and the points below are what the research does say.

  • Mechanism (preclinical): the BPC-157 review reports studies suggesting it acts on pathways in cell growth and angiogenesis while reducing inflammatory cytokines.13
  • The one human study: in a retrospective study of BPC-157 injected into the knee for chronic knee pain, 7 of 12 patients reported relief for more than 6 months.13
  • Tissue repair: tendon and ligament healing is slow in any case; no human trial of these peptides measured how long it takes with them.
  • GHK-Cu: a review reports skin effects from cosmetic products and wound healing in animals; the FDA notes limited human data on injectable GHK-Cu.143

GH peptides (ipamorelin, CJC-1295, GHRP-2, MK-677)

Growth hormone secretagogues act indirectly: they stimulate the pituitary to release GH, which raises IGF-1 and acts downstream. The gap between levels and visible results is wide, and outcome trials are few.

  • Hours: in volunteers, ipamorelin produced a single episode of GH release peaking at 0.67 hours, then a decline to negligible GH.4
  • Days: a single injection of CJC-1295 in healthy adults raised mean GH 2- to 10-fold for 6 days or more and mean IGF-I 1.5- to 3-fold for 9 to 11 days; after repeated doses IGF-I stayed above baseline for up to 28 days.5
  • Weeks: body composition changes are gradual and easy to miss day to day, which is why body measurements alongside subjective markers give a clearer picture. No trial of these peptides measured body composition over time.
  • Safety signal: the FDA notes a hip fracture trial of ibutamoren (MK-677) that was terminated early for a potential signal of congestive heart failure.3

TRT (testosterone enanthate, cypionate)

Testosterone acts on several systems, each on its own timeline. A review of replacement studies set out when each effect first appears and when it peaks.15

  • Weeks 3-6: effects on quality of life manifest within 3-4 weeks, and on depressive mood after 3-6 weeks, with a maximum after 18-30 weeks.15
  • Week 3 onward: effects on sexual interest appear after 3 weeks and plateau at 6 weeks; changes in erections and ejaculation may take up to 6 months.15
  • Weeks 12-16: changes in fat mass, lean body mass and muscle strength occur within 12-16 weeks and stabilise at 6-12 months.15
  • Months 3-12: effects on red blood cell production are evident at 3 months and peak at 9-12 months, which is one reason bloodwork timing matters.15

Why some people feel nothing

People starting a first protocol sometimes feel no different after a few weeks and conclude the compound is not working. Often the explanation lies elsewhere.

1

Reconstitution and dosing errors

If the bacteriostatic water volume is wrong, every dose drawn from that vial is off in proportion. Drawing 10 units instead of 20 halves the dose with no visible sign. The FDA has received adverse event reports that may be linked to people measuring incorrect doses of compounded semaglutide.17 The reconstitution calculator shows the units to draw for a target dose from the vial size and water volume. See the full reconstitution guide.

2

Product quality and storage issues

The FDA warns that GLP-1 products sold "for research purposes" are of unknown quality, and that counterfeit products can contain the wrong ingredient, too little, too much or none.17 Powder or solution exposed to heat or light may have degraded before use; approved labels protect from both.18 Certificates of analysis, where available, report one batch.

3

Compressed expectations from social media

Before-and-after posts compress months into one image. The phase 3 GLP-1 results above were measured at 68 and 72 weeks. For most compound classes, the trajectory is gradual.

4

Gradual change blindness

Changes that accumulate slowly (joint comfort, fat redistribution, sleep) are hard to see in real time, much as weight loss is noticed by someone who has not seen a person in a month rather than by the people who see them daily. Daily tracking leaves a record that shows trends experience misses.

5

Individual physiological variation

Body composition, baseline hormone levels, concurrent medications, sleep, training and genetics all bear on response. Trials show the spread: in SURMOUNT-1, 85% to 91% of people on tirzepatide lost 5% or more of body weight, so some did not.11

The tracking advantage

Subjective experience is a weak record. How things feel now is clear; last week is vague; three weeks ago is hard to recall reliably. That makes gradual change hard to detect without data.

Daily subjective markers (energy, mood, sleep quality, recovery, discomfort) build a dataset that shows trends day-to-day experience misses. A small average rise in energy over 3 weeks is not noticed day to day, but plotted alongside a saturation curve it can line up with levels building.

Weight is the familiar example. Daily weigh-ins move with water, food timing and hormonal cycles, which hides the trend; a 7-day rolling average shows it. The same applies to other markers.

Pattern recognition

Subjective data lining up with the pharmacokinetic curve, energy improving in the window a compound reaches 90% saturation, for example, turns "I think it might be working" into a pattern in the record. It is a correlation, not proof.

Patience vs adjusting

A hard question in any protocol is telling "it needs more time" from "something needs to change". There is no universal answer, but there are patterns.

More time is the likely answer when: it is still early for the compound class, dosing and reconstitution have been checked, and steady state has not been reached. A change before steady state means the original protocol was never fully tested.

A closer look is the likely answer when: it is well past the point the evidence above points to, dosing has been checked, and bloodwork shows whether the compound is having its expected effect. For GH peptides, IGF-1 before and after a few weeks is an objective check; a review describes IGF-1 as a stable indication of integrated GH secretion.16 Any change of dose or compound is for the person and their clinician.

Changing several variables at once (compound, dose, frequency, a new addition) makes it impossible to tell which one caused a change. Changing one thing at a time and giving it time keeps that clear. For more on combining compounds, see the peptide stacking guide.

Individual variation

The timelines in this article come from labels, trials and reviews where those exist, and are population averages, not predictions for any one person. Response varies with genetics, metabolism, body composition, concurrent medications, sleep, training and baseline physiology.

Frequently asked questions

What is the fastest-acting peptide?

By pharmacokinetics, ipamorelin is among the quickest: in volunteers its GH release peaked at 0.67 hours and its half-life was 2 hours.4 BPC-157's half-life was under 30 minutes in rats and dogs.2 Downstream effects such as body composition take weeks to months, and for research peptides no human outcome timeline was found.

How do you know if peptides have expired or gone bad?

Labels say not to use a reconstituted solution that is cloudy or contains particles.18 Many degradation pathways leave no visible sign, so time and temperature limits are the more reliable guide: Humatrope's reconstituted cartridges are stable for up to 28 days refrigerated, and the FDA recommends discarding multiple-dose compounded GLP-1 vials within 28 days after first use.1817

Do peptides build tolerance over time?

Evidence differs by class. For semaglutide, STEP 1 described a sustained reduction in body weight over 68 weeks of continued use.10 For GH secretagogues and healing peptides, no human study of tolerance was found; cycling is a community practice, not a trial result.

How long does BPC-157 take to work?

BPC-157's elimination half-life was under 30 minutes in rats and beagle dogs, so on that figure it would reach steady state within a few hours of consistent dosing.2 No human timeline for its effects was found: of 36 studies in a 2025 systematic review, 35 were preclinical.13

How long does semaglutide take to show results?

Semaglutide has a half-life of approximately 1 week and reaches steady state after 4 to 5 weeks of weekly doses.7 Wegovy titrates from 0.25 mg every 4 weeks to the maintenance dose from week 17.12 In STEP 1, mean body weight change at week 68 was -14.9% with semaglutide 2.4 mg against -2.4% with placebo.10

References

  1. Hallare J, Gerriets V. Elimination half-life of drugs. StatPearls (NCBI Bookshelf, PubMed record). 2025. pubmed.ncbi.nlm.nih.gov
  2. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022. pubmed.ncbi.nlm.nih.gov
  3. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). 2026. fda.gov
  4. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. pubmed.ncbi.nlm.nih.gov
  5. Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
  6. Antares Pharma (DailyMed). Xyosted (testosterone enanthate) injection label. 2026. dailymed.nlm.nih.gov
  7. Novo Nordisk (DailyMed). Ozempic (semaglutide) injection label. 2026. dailymed.nlm.nih.gov
  8. Eli Lilly (DailyMed). Mounjaro (tirzepatide) injection label. 2026. dailymed.nlm.nih.gov
  9. Cosette Pharmaceuticals (DailyMed). Vyleesi (bremelanotide) injection label. 2026. dailymed.nlm.nih.gov
  10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov
  11. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov
  12. Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov
  13. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov
  14. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. pubmed.ncbi.nlm.nih.gov
  15. Saad F et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011. pubmed.ncbi.nlm.nih.gov
  16. Cardoso LM et al. Acromegaly: biochemical diagnosis. Vitam Horm. 2026. pubmed.ncbi.nlm.nih.gov
  17. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 1 October 2026). 2026. fda.gov
  18. Eli Lilly (DailyMed). Humatrope (somatropin) label. 2026. dailymed.nlm.nih.gov